EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Clinical outcomes following PD-1 inhibitor elective discontinuation in cutaneous squamous cell carcinoma: exploring treatment de-escalation

Itamar Averbuch, Nofar Edri, Nethanel Asher, Gal Markel, Daniel Hendler, Hadas Ditzian Kugler, Eyal Yosefof, Noga Kurman

Cancer Immunology, Immunotherapy · 2025

DOI: 10.1007/s00262-025-04115-y ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Itamar Averbuch und 7 weiteren Autor:innen. Beteiligte Einrichtung: Davidoff Cancer Center, Rabin Medical Center - Beilinson Hospital, Petach Tikva, Israel. av.itamar@gmail.com. Hauptthemen laut MEDLINE: Skin Neoplasms, Carcinoma, Squamous Cell, Programmed Cell Death 1 Receptor, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Non-melanoma skin cancers (NMSC) are the most common malignancies worldwide. While early-stage lesions can be definitively treated with local therapies, advanced stage cutaneous squamous cell carcinoma (cSCC) often requires systemic treatments such as PD-1 inhibitors. These treatments may be administered for prolonged durations; this practice may lead to an unnecessary physical and financial toxicity. The purpose of this study was to evaluate the patterns of disease progression after anti-PD-1 therapy discontinuation in this group of patients. METHODS: This retrospective cohort study included patients diagnosed with advanced cSCC and treated with either cemiplimab or pembrolizumab from 2019 to 2024 at a single university-affiliated tertiary medical center. RESULTS: The cohort included 131 patients, with a 73% overall response rate. Among the 86 patients with either partial or complete response as the best response included in the final analysis, 40 (47%) patients had a treatment break for at least 3 months, and 46 (53%) continued without discontinuation to a maximal duration of 2 years. After a median follow-up of 29.9 months, 24 (60%) patients in the break group remained progression-free, systemic treatment-free, and alive throughout the follow-up. Four patients (10%) experienced disease progression. Among these, the best overall response was PR in three patients and CR in one patient. Nine (22.5%) patients died due to non-oncological reasons, two (5%) patients died from an unknown cause, and one (2.5%) due to treatment toxicity. The percentage of patients achieving CR was statistically significantly higher in the break group compared to the no-break group. CONCLUSIONS: Our findings advocate for a more tailored approach to the duration of PD-1 inhibitor therapy in cSCC, potentially reducing burdens of overtreatment. Future studies regarding establishing robust predictors for safe treatment discontinuation are required to enhance decision-making in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Skin NeoplasmsCarcinoma, Squamous CellProgrammed Cell Death 1 ReceptorImmune Checkpoint InhibitorsAntibodies, Monoclonal, HumanizedWithholding TreatmentHumansMaleFemaleRetrospective StudiesAgedMiddle AgedAged, 80 and overAdultTreatment Outcome

Stichwörter der Autor:innen

Anti-PD-1 therapy discontinuationCutaneous squamous cell carcinomaPD-1 inhibitors

Substanzen

Programmed Cell Death 1 ReceptorImmune Checkpoint InhibitorspembrolizumabAntibodies, Monoclonal, HumanizedPDCD1 protein, humancemiplimab

Autor:innen und Institutionen

  • Davidoff Cancer Center, Rabin Medical Center - Beilinson Hospital, Petach Tikva, Israel. av.itamar@gmail.com.
  • Faculty of Medicine and Health Sciences, Tel Aviv University, Tel Aviv, Israel. av.itamar@gmail.com.
  • Davidoff Cancer Center, Rabin Medical Center - Beilinson Hospital, Petach Tikva, Israel.
  • Faculty of Medicine and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
  • Otolaryngology Head and Neck Surgery Department, Rabin Medical Center - Beilinson Hospital, Petach Tikva, Israel.
  • Samueli Integrative Cancer Pioneering Institute, Rabin Medical Center, Petach Tikva, Israel.

Zitieren

APA

Averbuch, I., Edri, N., Asher, N., Markel, G., Hendler, D., Ditzian Kugler, H., Yosefof, E., & Kurman, N. (2025). Clinical outcomes following PD-1 inhibitor elective discontinuation in cutaneous squamous cell carcinoma: exploring treatment de-escalation. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-025-04115-y

Vancouver

Averbuch I, Edri N, Asher N, Markel G, Hendler D, Ditzian Kugler H, et al. Clinical outcomes following PD-1 inhibitor elective discontinuation in cutaneous squamous cell carcinoma: exploring treatment de-escalation. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-025-04115-y

BibTeX
@article{Averbuch2025,
  author = {Averbuch, Itamar and Edri, Nofar and Asher, Nethanel and Markel, Gal and Hendler, Daniel and Ditzian Kugler, Hadas and Yosefof, Eyal and Kurman, Noga},
  title = {Clinical outcomes following PD-1 inhibitor elective discontinuation in cutaneous squamous cell carcinoma: exploring treatment de-escalation},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2025},
  doi = {10.1007/s00262-025-04115-y}
}
Kostenlos starten →